You are here: Welcome » Gerald Evans

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Both sides next revision
gerald_evans [2022/05/04 15:56]
liam [Ontario Drug Policy Research Network] 		gerald_evans [2022/05/04 16:29] (current)
liam
Line 38: Line 38:
  
 Evans is a member of the [[Cancer Care Ontario]] subcommittee under [[Ontario Health]].((//Gerald Evans.// Institute for Clinical Evaluative Sciences. Retrieved May 4, 2022, from https://www.ices.on.ca/About-ICES/ICES-Scientists/E/Gerald-Evans/Bio)) Evans is a member of the [[Cancer Care Ontario]] subcommittee under [[Ontario Health]].((//Gerald Evans.// Institute for Clinical Evaluative Sciences. Retrieved May 4, 2022, from https://www.ices.on.ca/About-ICES/ICES-Scientists/E/Gerald-Evans/Bio))
 +
 ==== Ontario Drug Policy Research Network ==== ==== Ontario Drug Policy Research Network ====
  
Line 45: Line 46:
  
 Evans is a member of the Expert Committee for [[Reformulary]], an evidence-based list of drugs reviewed and recommended by the panel.((//Reformulary Expert Committee Members and Special Advisors.// DrugFinder. Retrieved May 4, 2022, from https://archive.ph/XLi9P)) Evans is a member of the Expert Committee for [[Reformulary]], an evidence-based list of drugs reviewed and recommended by the panel.((//Reformulary Expert Committee Members and Special Advisors.// DrugFinder. Retrieved May 4, 2022, from https://archive.ph/XLi9P))
 +
 +==== Critical Care Canada forum ====
 +
 +Evans has participated as a speaker at the [[Critical Care Canada Forum]], the official meeting of the [[Canadian Critical Care Society]].((//Dr. Gerald Evans.// Critical Care Canada Forum. Retrieved May 4, 2022, from https://archive.ph/bTAYs)) The Forum's 2021 webinars were sponsored by [[medical_technology_companies:Medtronic]], [[pharmaceutical_companies:Merck]], [[pharmaceutical_companies:Paladin Laboratories]], and [[medical_technology_companies:Masimo]].((//Sponsored Webinars 2021.// Critical Care Canada Forum. Retrieved May 4, 2022, from https://criticalcarecanada.com/sponsored-webinars-2021/))
 +
 +==== Canadian Lyme Disease Research Network ====
 +
 +Evans is a co-applicant on a grant for the [[Canadian Lyme Disease Research Network]], the project formerly led by Dr. [[Kieran Moore]].((//Gerald Evans Bio.// Canadian Lyme Disease Research Network. Retrieved May 4, 2022, from https://archive.ph/MMqiw))
 +
 ==== Ontario COVID-19 Science Advisory Table ==== ==== Ontario COVID-19 Science Advisory Table ====
  
 Evans is a member of the [[Ontario COVID-19 Science Advisory Table]], including as a member of the Behavioural Science Working Group.((//About Us.// Ontario COVID-19 Science Advisory Table. Retrieved April 28, 2022, from https://covid19-sciencetable.ca/about/)) Evans is a member of the [[Ontario COVID-19 Science Advisory Table]], including as a member of the Behavioural Science Working Group.((//About Us.// Ontario COVID-19 Science Advisory Table. Retrieved April 28, 2022, from https://covid19-sciencetable.ca/about/))
 +
 +===== Research =====
 +
 +==== COVID-19 ====
 +
 +Evans received research funding from the [[Southeastern Ontario Academic Medical Organization]] (SOAMO) for "synthesis and preclinical testing of novel small molecule therapies for [[COVID‐19]]."((Evans, G. (2021). //Declaration of Interest.// Ontario COVID-19 Science Advisory Table. https://web.archive.org/web/20220215130832/https://covid19-sciencetable.ca/wp-content/uploads/2020/07/Declaration-of-Interest_Science-Table_Gerald-Evans_20210827.pdf))
  
 ===== Relationship with Pharmaceutical Companies ===== ===== Relationship with Pharmaceutical Companies =====
  
 Evans has received research funding from [[pharmaceutical_companies:Biocryst]].((Stiver, H. G., Evans, G. A., Aoki, F. Y., Allen, U. D., & Laverdière, M. (2015). //Guidance on The Use of Antiviral Drugs for Influenza in Acute Care Facilities in Canada, 2014-2015.// Canadian Journal of Infectious Diseases and Medical Microbiology, 26(1), e5–e8. https://doi.org/10.1155/2015/371840)) Evans has received research funding from [[pharmaceutical_companies:Biocryst]].((Stiver, H. G., Evans, G. A., Aoki, F. Y., Allen, U. D., & Laverdière, M. (2015). //Guidance on The Use of Antiviral Drugs for Influenza in Acute Care Facilities in Canada, 2014-2015.// Canadian Journal of Infectious Diseases and Medical Microbiology, 26(1), e5–e8. https://doi.org/10.1155/2015/371840))
Back to top